Solid Biosciences Llc Stock Today

SLDB Stock  USD 5.87  0.10  1.73%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 81

 
High
 
Low
Very High
Solid Biosciences is trading at 5.87 as of the 11th of November 2024, a 1.73 percent increase since the beginning of the trading day. The stock's open price was 5.77. Solid Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Solid Biosciences LLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of October 2024 and ending today, the 11th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
26th of January 2018
Category
Healthcare
Classification
Health Care
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Solid Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 39.95 M outstanding shares of which 1.77 M shares are at this time shorted by private and institutional investors with about 5.96 trading days to cover. More on Solid Biosciences LLC

Moving together with Solid Stock

  0.63ME 23Andme HoldingPairCorr
  0.87VALN Valneva SE ADRPairCorr

Moving against Solid Stock

  0.71DRUG Bright Minds Biosciences Downward RallyPairCorr
  0.63DMAC DiaMedica Therapeutics Earnings Call TodayPairCorr
  0.54VCYT VeracytePairCorr
  0.51VERA Vera TherapeuticsPairCorr
  0.41DSGN Design Therapeutics Earnings Call TodayPairCorr
  0.4DNLI Denali TherapeuticsPairCorr

Solid Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentAlexander Cumbo
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.04940.0358
Significantly Up
Slightly volatile
Total Current Liabilities18.1 M14.5 M
Fairly Up
Slightly volatile
Non Current Liabilities Total29.3 M23.9 M
Fairly Up
Slightly volatile
Total Assets152.1 M164.9 M
Significantly Down
Slightly volatile
Total Current Assets135.9 M129.7 M
Sufficiently Up
Slightly volatile
Debt Levels
Solid Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Solid Biosciences' financial leverage. It provides some insight into what part of Solid Biosciences' total assets is financed by creditors.
Liquidity
Solid Biosciences LLC currently holds 26.27 M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest the company is not taking enough advantage from borrowing. Solid Biosciences LLC has a current ratio of 7.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Solid Biosciences' use of debt, we should always consider it together with its cash and equity.

Sale Purchase Of Stock

69.57 Million
Solid Biosciences LLC (SLDB) is traded on NASDAQ Exchange in USA. It is located in 500 Rutherford Avenue, Charlestown, MA, United States, 02129 and employs 88 people. Solid Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 234.53 M. Solid Biosciences LLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 39.95 M outstanding shares of which 1.77 M shares are at this time shorted by private and institutional investors with about 5.96 trading days to cover. Solid Biosciences LLC currently holds about 162.88 M in cash with (94.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44.
Check Solid Biosciences Probability Of Bankruptcy
Ownership Allocation
Solid Biosciences LLC shows a total of 39.95 Million outstanding shares. The majority of Solid Biosciences LLC outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Solid Biosciences to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Solid Biosciences LLC. Please pay attention to any change in the institutional holdings of Solid Biosciences LLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Solid Ownership Details

Solid Stock Institutional Holders

InstituionRecorded OnShares
Finepoint Capital Lp2024-06-30
961.3 K
Hhg Plc2024-06-30
753 K
Geode Capital Management, Llc2024-06-30
513.5 K
Laurion Capital Management Lp2024-06-30
489.7 K
Silverarc Capital Management, Llc2024-06-30
473 K
Monashee Investment Management Llc2024-06-30
450 K
Alyeska Investment Group, L.p.2024-06-30
446.4 K
Walleye Trading Advisors, Llc2024-06-30
412 K
State Street Corp2024-06-30
404.4 K
Perceptive Advisors Llc2024-06-30
6.9 M
Ra Capital Management, Llc2024-06-30
4.3 M
View Solid Biosciences Diagnostics

Solid Biosciences Historical Income Statement

At present, Solid Biosciences' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 24.7 M, whereas Selling General Administrative is forecasted to decline to about 20.8 M. View More Fundamentals

Solid Stock Against Markets

Solid Biosciences Corporate Executives

Elected by the shareholders, the Solid Biosciences' board of directors comprises two types of representatives: Solid Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Solid. The board's role is to monitor Solid Biosciences' management team and ensure that shareholders' interests are well served. Solid Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Solid Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kevin CFACFO TreasurerProfile
When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.04)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.35)
Return On Equity
(0.66)
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.